In what situations would you consider ESAs in hospitalized patients with severe anemia for indications other than CKD or myelosuppressive chemotherapy (e.g., ACD, hemorrhage)?
In deciding on the risk-benefit of ESAs in patients with severe anemia due to bleeding and/or inflammatory disease, there are two considerations. The first is the severity of the anemia and consequently, the time to initial response. Using the standard dose of ESAs, it may take 8 to 12 weeks to achieve the target hemoglobin of 10 g. Thus, patients with severe anemia who need a rise in hemoglobin quickly may not benefit from ESAs. However, high-intensity treatment with ESA may achieve a rapid response but with the risk of thrombotic complications.
Thus, in our patients, we do not consider ESAa in patients with prior thrombosis, current history of cancer, or need for a rapid rise in hemoglobin. Moreover, we would only consider ESAs if there i...
Join for free or sign in to see the full answer